Features include very common findings: Abnormal respiratory system physiology, Hypersensitivity pneumonitis, and Immunologic hypersensitivity; and common findings: Weight loss, Difficulty breathing (respiratory insufficiency), Dyspnea, and Abnormal tracheobronchial morphology and others. 19 total HPO annotations.

Biomarker and diagnostic research for chronic beryllium disease has been reported in the published literature.

No approved treatments are currently available for chronic beryllium disease. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for chronic beryllium disease, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for chronic beryllium disease. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 3 very common features, 13 common features.

Estimated prevalence: Unknown (Unknown prevalence).

No clinical trials have been registered for chronic beryllium disease.

23 publications have been identified in PubMed for chronic beryllium disease. Research spans Basic Science / Preclinical (32%), Epidemiology / Natural History (27%), and Review / Meta-Analysis (14%).